FDA Whistleblowers Will Get Cultural – Not Structural – Relief, Hamburg Says
Executive Summary
FDA Commissioner designate Margaret Hamburg committed to cultural rather than structural change when called on by the Senate HELP committee to ensure the integrity of scientific discourse at FDA
You may also be interested in...
Avandia Advisory Committee: Can Poking Old Wounds Be Good For FDA?
Two advisory panels will revisit the question of whether FDA should withdraw GlaxoSmithKline’s Avandia from the market as a reevaluation of the cardiovascular trial produces results similar to the original findings; the data does not seem to offer much more clarity, but does give the agency a chance to argue it handled previous controversies well.
Hamburg Is One Step Closer To Commissioner’s Office As Senate Panel Endorses Nomination
Senate Health panel approves Hamburg’s nomination as FDA commissioner, with full Senate vote expected soon.
Commissioner Nominee Hamburg Questioned On FDA’s Role In Health Reform
Congressional questioning during the confirmation hearing of FDA Commissioner-designate Margaret Hamburg May 7 underscored the influence the probable agency chief would have in an era of health care reform